| Dr Bradley Vincent Watts, MD | |
|
215 N. Main St, White River Junction, VT 05009-0001 | |
| (802) 295-9363 | |
| Not Available |
| Full Name | Dr Bradley Vincent Watts |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 215 N. Main St, White River Junction, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952490658 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 042-0009578 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradley Vincent Watts, MD 215 N. Main St, White River Junction, VT 05009-0001 Ph: (802) 295-9363 | Dr Bradley Vincent Watts, MD 215 N. Main St, White River Junction, VT 05009-0001 Ph: (802) 295-9363 |
News Archive
Obstructive sleep apnea (OSA) is a chronic condition in which enhancement of patient self-efficacy is critical for long-term management.
Giving mice a gene mutation linked to eating disorders in people causes feeding and behavior abnormalities similar to symptoms often seen in patients with eating disorders. Only female mice are affected by the gene mutation, and some of the abnormalities in the female mice depend on whether they are housed alone or together with other mice.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
A new study by the IFCC‑IOF Committee for Bone Metabolism shows large within- and between-assay variation for ß-CTX measurement; until harmonization is achieved, proposes measuring ß-CTX by the same assay on EDTA plasma, especially for research.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
› Verified 5 days ago
Dr. John L Hammel, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 215 N Main St, Va Medical Center, Mental Health Department, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-296-6342 | |
Dr. Andrew S. Pomerantz, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, Mental Health 116a, White River Junction, VT 05001 Phone: 802-295-9363 Fax: 802-296-6389 | |
Stephen Bettwieser, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-296-5188 | |
Lisa Ann Lambert, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 | |
Dr. Linda M Nagy, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, Vamc 116a, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-296-6389 | |
Melissa Moate Ley-thomson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 | |
Dr. Jonathan Carl Schwartz, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-296-6342 |